Patricia Udaondo, MD, PhD; Michela Cimberle , 2025-04-23 13:28:00
April 23, 2025
5 min watch
SEVILLE, Spain — In this Healio Video Perspective from the Congress on Controversies in Ophthalmology, Patricia Udaondo, MD, PhD, highlights the meeting’s debate sessions on new anti-VEGF therapies.
She addressed treatment durability, maintenance of functional and anatomical outcomes, safety and reduced injection burden.
“We need to go deeper with this kind of analysis to understand the real benefit to the patient and the system,” she said.
Udaondo also discussed biosimilars, which are a cost-saving option but have not kept pace with newer, longer-acting anti-VEGFs.
“The new generation of treatments have additional benefits that we cannot [obtain] with biosimilars,” she said.
Sources/Disclosures
Collapse
Zur D, et al. Medical retina 3: Novel technologies and therapies in retinal diseases. Presented at: Congress on Controversies in Ophthalmology; April 4-5, 2025; Seville, Spain.
Disclosures:
Udaondo reports consulting for AbbVie, Adverum, Alimera, Bausch + Lomb, Bayer, Boehringer Ingelheim, Brill Pharma, EyePoint Pharmaceuticals, Ocular Therapeutix, Outlook Therapeutics, Roche and Sandoz.
